Lexicon Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 6 Sell calls were followed by a 23% average decline over the next quarter.
- Recent price momentum is -7.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 99.4% | Better than 99% |
| Operating margin | -98.2% | Better than 7% |
| Net margin | -101.1% | Better than 7% |
| Return on equity | -39.7% | Better than 11% |
| Return on invested capital | -23.0% | Better than 12% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -33.5% | Better than 15% |
| 6-month return | -29.2% | Better than 19% |
| 12-month return (ex latest month) | 11.2% | Better than 47% |
| Distance below 52-week high | 42.9% | Better than 25% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.9x | Better than 85% |
| Debt to assets | 34.0% | Better than 35% |
| Interest coverage | -5.0x | Better than 17% |
| Free cash flow / net income | 87.4% | Better than 30% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 282.4% | Better than 97% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 1.67
- Open
- 1.66
- Day range
- 1.47 - 1.70
- Avg price
- 1.57
- Volume
- 4.21M
- Turnover
- 6.62M
- Turnover ratei
- 1.92%
- Volume ratioi
- 2.24
- Amplitudei
- 13.75%
- 52-week rangei
- 1.10 - 2.68
Valuation
- P/Ei
- -10.93
- P/E (TTM)i
- -10.20
- P/Bi
- 4.16
- EPSi
- -0.14
- Book value / shi
- 0.37
- Net profit
- -62.33M
- Net assets
- 163.85M
Share structure
- Market cap
- 681.21M
- Float capi
- 335.43M
- Shares out
- 445.23M
- Float sharesi
- 219.24M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
42.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.45M net over the window
Short interest
- Shares short
- 25.88M
- % of floati
- 5.82%
- Days to coveri
- 14.04
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals last traded at 1.53. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Lexicon Pharmaceuticals's market cap?
About 681.21M.
What is the P/E ratio of Lexicon Pharmaceuticals?
The trailing twelve-month P/E is -10.20. The Valuation tab shows it against the stock's own five-year range.
Does Lexicon Pharmaceuticals pay a dividend?
Lexicon Pharmaceuticals does not currently pay a regular dividend.
Is Lexicon Pharmaceuticals a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 5.85, which implies 282.4% upside from the current price. This is not investment advice.
What is Lexicon Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Lexicon Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.
Lexicon Pharmaceuticals discussion 0 comments